Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | HTR2B | P41595 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5643492 | 0.86 | HTR2A (0.32) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL5650147 | 0.84 | CHRM3 (0.32) | HTR2AHTR2CHTR2B | |
| SCHEMBL30785559 | 0.78 | ALDH1A1 (0.37) | HTR2AHTR2CHTR2BCYP2C19 | |
| SCHEMBL187289 | 0.74 | BCHE (0.35) | FAAH | |
| SCHEMBL16220577 | 0.73 | MEN1 (0.34) | MEN1GABRA1CYP2C19GABRB2KMT2A | |
| SCHEMBL16380132 | 0.72 | MEN1 (0.33) | MEN1GABRA1CYP2C19GABRB2KMT2A | |
| SCHEMBL3337356 | 0.72 | PDCD1 (0.35) | HTR2AHTR2CHTR2BMEN1GABRA1 | |
| SCHEMBL19042352 | 0.72 | MEN1 (0.33) | MEN1GABRA1CYP2C19GABRB2KMT2A | |
| Hydrochloric Acid SCHEMBL15021048 | 0.70 | PDCD1 (0.35) | MEN1GABRA1CYP2C19GABRB2KMT2A | |
| SCHEMBL19131408 | 0.69 | CHRNB2 (0.35) | HTR2AHTR2CHTR2BMEN1GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991989-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | PFIZER (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2991989-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | PFIZER (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9296761-B2 | Triazine derivatives | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296761-B2 | Triazine derivatives | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296761-B2 | Triazine derivatives | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2991989-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | Pfizer Inc. (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20150353579-A1 | Triazine Derivatives | PFIZER (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353579-A1 | Triazine Derivatives | PFIZER (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353579-A1 | Triazine Derivatives | PFIZER (US) | 2015-12-10 | — | — | US | disclosed |
| US-9145427-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-09-29 | — | — | US | disclosed |
| WO-2014177977-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | PFIZER INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20140329820-A1 | Triazine Derivatives | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2014177977-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | PFIZER INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20140329820-A1 | Triazine Derivatives | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329820-A1 | Triazine Derivatives | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-7265128-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265128-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265128-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-03-30 | — | — | US | disclosed |
| WO-2004064778-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO. INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329820-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | HTR2A 589/4885HTR2C 871/4885HTR2B 619/4885 |
| US-20150353579-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | HTR2A 589/4885HTR2C 871/4885HTR2B 619/4885 |
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | HTR2A 2387/4885HTR2C 2255/4885HTR2B 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.